No effect of resveratrol on VLDL‐TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease

Poulsen, Mikael Kjær; Nellemann, Birgitte; Bibby, Bo Martin; Stødkilde-Jørgensen, Hans; Pedersen, Steen B.; Grønbæk, Henning; Nielsén, Sören

doi:10.1111/dom.13409

Cited by 32 publications

(34 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, a variety of lipid metabolism-related regulatory factors are closely associated with NAFLD. However, whether these regulatory factors are an effective target for the treatment of NAFLD remains to be elucidated through further research ( 51 , 52 ).…”

Section: Lipid Metabolism In Nafldmentioning

confidence: 99%

Abnormal metabolic processes involved in the pathogenesis of non‑alcoholic fatty liver disease (Review)

Shao

Qin

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases and can lead to liver cirrhosis or liver cancer in severe cases. In recent years, the incidence of NAFLD has increased substantially. The trend has continued to increase and has become a key point of concern for health systems. NAFLD is often associated with metabolic abnormalities caused by increased visceral obesity, including insulin resistance, diabetes mellitus, hypertension, dyslipidemia, atherosclerosis and systemic microinflammation. Therefore, the pathophysiological mechanisms of NAFLD must be clarified to develop new drug treatment strategies. Recently, researchers have conducted numerous studies on the pathogenesis of NAFLD and have identified various important regulatory factors and potential molecular mechanisms, providing new targets and a theoretical basis for the treatment of NAFLD. However, the pathogenesis of NAFLD is extremely complex and involves the interrelationship and influence of multiple organs and systems. Therefore, the condition must be explored further. In the present review, the abnormal metabolic process, including glucose, lipid, amino acid, bile acid and iron metabolism are reviewed. It was concluded that NAFLD is associated with an imbalanced metabolic network that involves glucose, lipids, amino acids, bile acids and iron, and lipid metabolism is the core metabolic process. The current study aimed to provide evidence and hypotheses for research and clinical treatment of NAFLD.

show abstract

Section: Lipid Metabolism In Nafldmentioning

confidence: 99%

Abnormal metabolic processes involved in the pathogenesis of non‑alcoholic fatty liver disease (Review)

Shao

Qin

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Out of the eight RCTs [ 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ] assessing phytochemicals, four RCTs qualified for qualitative analysis only and used the DS pinitol [ 28 ], catechins [ 29 ], and resistant starches [ 30 , 31 ]. The other four RCTs [ 24 , 25 , 26 , 27 ], assessing the efficacy of resveratrol using MRS in a total of 174 patients, were included in a meta-analysis. Chachay et al [ 24 ], Heebøll et al [ 25 ], and Poulsen et al [ 27 ] studied patients with NAFLD.…”

Section: Resultsmentioning

confidence: 99%

“…The other four RCTs [ 24 , 25 , 26 , 27 ], assessing the efficacy of resveratrol using MRS in a total of 174 patients, were included in a meta-analysis. Chachay et al [ 24 ], Heebøll et al [ 25 ], and Poulsen et al [ 27 ] studied patients with NAFLD. Kantartzis et al [ 26 ] studied insulin resistant patients.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of Dietary Supplements to Reduce Liver Fat

et al. 2020

View full text Add to dashboard Cite

Liver fat accumulation is an important pathophysiological feature of non-alcoholic fatty liver disease that may be modulated by dietary supplements (DS). A systematic search of the literature was conducted for randomized controlled trials (RCTs) pertaining to the effect of a DS on liver fat as assessed using quantitative tomographic imaging in human adults. Where feasible, data were pooled, and meta-analyses conducted using random-effect model. Quality assessment was done according the Cochrane Collaboration’s tool for assessing risk of bias. Twenty RCTs, involving 1171 overweight and obese adults, of which 36% were females, with or without comorbidities, were included. Only RCTs assessing omega-3 fatty acids (n = 4) and resveratrol (n = 4) qualified for meta-analysis. Results did neither favor omega-3 (effect size −1.17; weighted mean difference (WMD) (95% confidence interval (CI)) −3.62, 1.28; p < 0.001) nor resveratrol supplementation (0.18; 95% CI −1.08, 1.43; p = 0.27). The findings of the qualitatively summarized RCTs suggested that catechins (n = 1), Lactobacillus reuteri (n = 1), and carnitine (n = 1) may reduce liver fat. All other DS did not show any influence. The current evidence is scarce, of limited quality and does not support DS use to reduce liver fat. Further well-designed trials are warranted.

show abstract

“…In another clinical trial (NCT01446276), a long-term (6 mo) and high-dose (500 mg 3 times daily) resveratrol treatment did not improve either basal or insulin-mediated VLDL-TG (very-low-density lipoprotein-triglycerides) secretion, oxidation, or clearance rates, nor did it affect palmitate or glucose turnover in nondiabetic, upper-body obese men with NAFLD. Likewise, no changes in body composition or liver fat content occurred following resveratrol compared with placebo treatment [141]. Therefore, more studies are needed to confirm the clinical application of resveratrol in treatment of liver fibrosis.…”

Section: Clinical Trialsmentioning

confidence: 99%

Fighting Liver Fibrosis with Naturally Occurring Antioxidants

et al. 2018

View full text Add to dashboard Cite

Liver fibrosis is a wound-healing response characterized by the accumulation of extracellular matrix following various liver injuries, which results in the deformation of the normal liver architecture and the development of liver cirrhosis and even hepatocellular carcinoma. Numerous in vitro and in vivo studies indicated that oxidative stress mediates the initiation and progression of liver fibrosis. Overaccumulation of reactive oxygen species disrupts macromolecules, induces necrosis and apoptosis of hepatocytes, stimulates the production of pro-fibrogenic mediators, and directly activates hepatic stellate cells, thereby resulting in liver damage and initiating liver fibrosis. Ameliorating oxidative stress is a potential therapeutic strategy for the treatment of liver fibrosis. Natural antioxidants have attracted increasing attention in treating liver fibrosis due to their safety and efficacy. In this review, the pathogenesis of liver fibrosis and the role of oxidative stress in liver fibrosis were discussed. Naturally occurring antioxidants that can treat and prevent liver fibrosis were summarized. Advances in clinical trials were also presented. The main purpose of this review is to provide a comprehensive and up-to-date knowledge from the biological importance of oxidative stress in liver fibrosis to representative antioxidants for treating liver fibrosis. Naturally occurring antioxidants show a potential for further investigations as lead compounds in fighting liver fibrosis.

show abstract

No effect of resveratrol on VLDL‐TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease

Cited by 32 publications

References 16 publications

Abnormal metabolic processes involved in the pathogenesis of non‑alcoholic fatty liver disease (Review)

Abnormal metabolic processes involved in the pathogenesis of non‑alcoholic fatty liver disease (Review)

Efficacy of Dietary Supplements to Reduce Liver Fat

Fighting Liver Fibrosis with Naturally Occurring Antioxidants

Contact Info

Product

Resources

About